SynthesisFrontiers in pharmacology2026
The efficacy and safety of Chaihu guizhi ganjiang tang for type 2 diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathological mechanisms of type 2 diabetes mellitus (T2DM) are complex and necessitate multi-target intervention strategies. Chaihu Guizhi Ganjiang Tang (CHGZGJT), a classical formula derived from the ancient canonical text Methods: This study was registered on the PROSPERO platform. Eight Chinese and English databases and two clinical trial registries were systematically searched, and 12 clinical controlled trials involving a total of 883 patients were ultimately included. Meta-analysis were performed using R software to assess efficacy and safety. Results: The meta-analysis suggested that CHGZGJT combined with conventional treatment significantly reduced glycated hemoglobin (HbA1c, MD = -0.69%), fasting plasma glucose (FPG, MD = -0.86 mmol/L), and 2-h postprandial glucose (2hPG, MD = -0.74 mmol/L) in patients with T2DM. At the mechanistic level, this regimen significantly decreased fasting insulin (FINS, MD = -2.08 µIU/mL) and the homeostasis model assessment of insulin resistance (HOMA-IR, MD = -0.79), improved islet β-cell function (HOMA-β, MD = 5.13), and lowered total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels, with a lower risk of adverse events (RR = 0.44). Conclusion: CHGZGJT may improve glycemic control, insulin resistance, β-cell function, and the lipid profile in patients with T2DM, with a favorable safety profile for short-term administration. However, the quality of evidence from the included studies was low to moderate, and high-quality clinical trials are still warranted to further verify its long-term efficacy and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.